SARS-CoV Spike Antibody | 3223

SARS-CoV Spike Antibody | 3223 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Virus

Homology: Predicted reactivity based on immunogen sequence: SARS-CoV2 Spike protein: (identity 65%, homology 88%)

Immunogen: Anti-SARS-CoV Spike antibody (3223) was raised against a peptide corresponding to 17 amino acids near the center of SARS-CoV Spike glycoprotein.
The immunogen is located within amino acids 550-600 of SARS-CoV Spike.

Research Area: Infectious Disease, COVID-19

Tested Application: E

Application: SARS-CoV Spike antibody can be used for the detection of SARS-CoV Spike protein in ELISA. It will detect 2 ng of free peptide at 1 μg/mL.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: SARS-CoV Spike has one isoform (1255aa) .

Purification: SARS-CoV Spike Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: SARS-CoV Spike Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: SARS-CoV Spike antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: SARS-CoV Spike antibody: E2, Spike glycoprotein, E2, S glycoprotein

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome) . Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.